All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Rajneesh Nath, Banner Gateway Medical Center, Gilbert, US. We asked, Does Iomab-B conditioning spare side effects compared with conventional conditioning?
SIERRA trial: Does Iomab-B conditioning spare side effects compared with conventional conditioning?
Nath outlines results from the phase III SIERRA trial, observing the toxicity of lomab-B conditioning in older patients with relapsed/refractory AML. He highlights an improved toxicity profile with Iomab-B conditioning compared with conventional care, including reduced rates of sepsis, febrile neutropenia, and mucositis.
ISAL 2019 | Targets for immunotherapy in acute myeloid leukemia
Gail Roboz presented a talk discussing the targets for immunotherapy in acute myeloid leukemia (AML) at the ISAL 2019 congress
How safe and efficacious is conditioning with radiolabeled anti-CD45 antibody 211-At-BC8-B10?
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Brenda Sandmaier, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How...
Subscribe to get the best content related to AML delivered to your inbox